NVIDIA
NVDA
Tesla
TSLA
Super Micro Computer
SMCI
4
Palantir
PLTR
5
Applovin
APP
US Stock MarketDetailed Quotes
LRMR Larimar Therapeutics
- 2.930
- -0.020-0.68%
Close Feb 26 16:00 ET
- 2.970
- +0.040+1.37%
Post 20:01 ET
186.95MMarket Cap-2.55P/E (TTM)
3.090High2.895Low503.37KVolume2.960Open2.950Pre Close1.49MTurnover1.62%Turnover RatioLossP/E (Static)63.81MShares11.97052wk High0.94P/B91.20MFloat Cap2.88052wk Low--Dividend TTM31.13MShs Float664.320Historical High--Div YieldTTM6.61%Amplitude1.530Historical Low2.956Avg Price1Lot Size
Larimar Therapeutics News
JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $21
Truist Financial Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $18
Truist Sees 'Significant Upside' for Larimar Therapeutics, Starts With a Buy
Truist Initiates Larimar Therapeutics at Buy With $18 Price Target
Larimar Therapeutics Analyst Ratings
H.C. Wainwright Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $15
JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $21
JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $21
JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $21
Baird Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $13
Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $26
A Quick Look at Today's Ratings for Larimar Therapeutics(LRMR.US), With a Forecast Between $14 to $36
Analysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR) and Ascendis Pharma (ASND)
Promising Developments and Strategic Regulatory Support Justify Buy Rating for Larimar Therapeutics
Larimar Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Larimar Therapeutics, Maintains $15 Price Target
LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $36
Positive Outlook on Larimar Therapeutics' Nomlabofusp for Friedreich's Ataxia: Analyst Recommends Buy Rating
JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $21
H.C. Wainwright Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $15